Good day, ladies and gentlemen, and welcome to the Allscripts third quarter 2021 earnings conference call. All lines have been placed on a listen-only mode, and the floor will be open for your questions and comments following the presentation. At this time, it is my pleasure to turn the floor over to your host, Jenny Gelinas. Ma'am, the floor is yours. Thank you very much. Good afternoon, and welcome to the Allscripts third quarter 2021 earnings conference call. Our speakers today are Paul Black, Allscripts Chief Executive Officer, and Rick Poulton, our President and Chief Financial Officer. We will be making a number of forward-looking statements during the presentation and the Q&A part of the call. These statements are based on our current expectations and involve a number of risks and uncertainties that could cause our actual results to vary materially. We undertake no obligation to revise these forward-looking statements in light of the new information or future events. Please refer to our earnings release and SEC filings for more information regarding the risk factors that may affect our results. Please reference the GAAP and non-GAAP financial statements, as well as non-GAAP tables in our earnings release and the supplemental workbook that are both available on our investor relations website. With that, I'm gonna hand the call over to Paul Black. Thanks, Jenny, and welcome to your new role. Welcome everybody else to the call today. We appreciate your interest in Allscripts. Today, I'd like to cover my view of the industry, the quarter, and our long-standing relevance to healthcare. As this global industry continues to manage through the pandemic, we're seeing innovations introduced to address newly exposed needs. You see this with a significant rise in telemedicine technology, options, and growing patient usage and expectations of these tools. To have the ability to reach patients anywhere is a game changer for providers in advancing the methods in which humans receive the care that they need. The rise of consumerism in healthcare and the importance of opening the digital front door for patients to engage their health has transformed how care is delivered, and it's here to stay. Patients now demand access to care beyond the four walls of the practice or hospital on their schedule, at their convenience, and without a long wait. Healthcare providers that embrace the rise of the patient as a consumer and the importance of capturing and harnessing analytics available which inform decision-making will expand their brands and catchment over the next two to four years. Healthcare technology is central to the strategy, which is better positioned for success when clinicians' patients have access to a complete and community view of the integrated record. Turning to the quarter. I'm pleased with our solid third quarter financial results, which represent the continuation of our strong performance this year. The results reflect decisive actions we have taken since the beginning of the COVID-19 pandemic and the efforts of the Allscripts teams located around the globe. During the quarter, we were awarded a contract extension from the National Institutes of Health Clinical Center, an important research hospital located on the NIH campus in Bethesda, Maryland. The hospital and research institute have been a valued Allscripts client since 1976. They represent the largest hospital devoted to research in the country. This renewal will extend NIH's use of Sunrise for at least five additional years. It also expands a purchasing ceiling under the agreement, enabling the U.S. federal government to purchase additional solutions through this contract vehicle. In California, Lompoc Valley Medical Center signed a 10-year agreement for Sunrise Community Care deployed on Microsoft Azure. In Iowa, Shenandoah Medical Center also signed a 10-year agreement for Sunrise Community Care. Shenandoah Medical Center sought a superior integrated EHR to address the needs of an important community hospital. A new client, Wilson N. Jones Regional Medical Center also signed a 10-year agreement for Sunrise Community Care. A facility with 214 licensed beds, they care for families in four counties of North Texas and Southern Oklahoma. Allscripts' international business also made progress this quarter. Our team won its first new client in New Zealand, Waikato District Health Board, who selected our anesthesia solution. For Allscripts, this win represents a significant opportunity to grow our business in New Zealand. We're also pleased to continue with our military contracts overseas, who are prepping for new upgrades and add-on capabilities. Since we last reported, we hosted our flagship client event, the Allscripts Client Experience, at the end of August in the United States. We hosted similar ACE events in the United Kingdom, Canada, Singapore, and Australia. Approximately 3,500 clients, partners, and associates attended the virtual events, which featured three days of education, networking, and fun. With more than 180 sessions completed, 50+ marketplace booths visited, and $35,000 raised for our give back partner, Reach Out and Read, ACE was a huge success. We also had our global impact event during the quarter. Allscripts employees around the world participated in the global impact event, providing various types of services and financial support to numerous charities. I'm quite proud of the work that we do, not only during this annual event, but also throughout the entire year, giving back to those in need. We call it winning in our communities. An incredible amount of change in healthcare has occurred over the last 20 months. A new pressure around staffing shortages, wage inflation, supply chain costs have created a strategic refocus on this dimension of our solutions. Revenue cycle, once relegated as tactical, is now a strategic part of a healthcare organization's success. Organizations are devoting their focus not only to treating patients with pressing needs, but also restoring their financial health. We are strengthening clients' financial chassis by our revenue cycle center of excellence proactive monitoring services. With our collaboration, we're seeing clients achieve record cash levels, substantial reductions in denials, and significant improvements in accounts receivable balances. This has all been driven through transparency into actionable data that financial managers need to effectively run their organizations every day. Our clients' improvements in performance are evidence of the impact of a truly integrated clinical and financial platform, combined with proactive as-a-service analytics. With a focus on visibility and clinician fatigue, we're also co-creating with our clients to build an individualized experience with elegance and simplicity, placing the human experience at the center of everything we do. This practice is called human-centered design. It's a thorough process that's been refined over the last three decades and puts the focus not only on the user and the workflow, but the human engaging with technology or the human experience. Applied across multiple industries, the human-centered design process lives where business, development, product, and design meet. This approach leverages the concept of personas, a representation of the problems, needs, goals, and behavior of a specific group, such as researchers, doctors, nurses, or CFOs. Personas are collections of relevant information and insight known to our Allscripts designers to create a shared understanding of what users want. It's based on research, testing, and feedback from clients during the development cycle. These personas are then tested and refined with our clients as we create unique and distinctive solutions that provide the intended experience. Looking forward, we will continue to drive our initiatives and grow our strategic partnerships, such as with Microsoft, as we deliver a true platform of health powered by the cloud that connects patients and providers through all points of care. To summarize, we have built a sustainable business model that delivers innovation and value to our clients. We have improved clinical outcomes at the point of care and strengthened financial performance across all facets of our clients' operations. We have delivered strong results for our shareholders with expanded margins and free cash flow that enable us to reinvest in the business and return substantial amounts of capital at the same time. I continue to be optimistic about our performance in 2021 and beyond. With that, I'll turn the call over to Rick Poulton, Allscripts President and CFO. Okay. Thank you, Paul, and thanks everybody for joining us today. Just one more reminder, as Jenny indicated, additional financial details are available in the supplemental financial data workbook that's posted to our investor relations website. We were very pleased with our financial performance in the third quarter, where we saw the continuation of positive trends that we'd experienced all year. We benefited from continued discipline in managing our cost structure, and this drove significant operating leverage, allowing us to report significant year-over-year growth in Adjusted EBITDA, earnings per share, and free cash flow. It resulted in our highest quarterly Adjusted EBITDA margin of the year. With that overview, let me highlight a few items. We reported $166 million of new bookings in the quarter, which was up 4% on a year-over-year basis. Revenue in the quarter was $369 million, up 1% year-over-year. As was the case last quarter, our revenue results are really a tale of two different stories. As such, we have modified our segment reporting this quarter to provide investors greater transparency on our business. These new segments better reflect the market dynamics in which we compete, as well as the way we are now managing the business from a resource allocation and leadership perspective. The Hospitals and Large Physician Practices segment represents our Sunrise, Paragon, and TouchWorks solutions, along with several other owned and third-party services and solutions that are geared toward health systems and large independent physician practices. Our Veradigm segment reflects the provider solutions that we have geared toward our smaller physician practice network, as well as the payer and life science relationships that we enable access to that network. In this regard, with this presentation, we now show the full asset base and performance of Veradigm in one place. The details of these segments can be found in tables four and five of the supplemental workbook that I referred to earlier. Veradigm revenue grew 10% year-over-year in line with our expectations. Our Veradigm business is a uniquely scaled three-sided platform, bringing together providers and their patients alongside payers and life science organizations. It's built to capitalize on and benefit from the secular trends towards advanced solutions for workflow automation, network orchestration, clinical research as a care option, and management of at-risk populations. The breadth of our network of primary care and specialty care physicians is unique in size, and we are bringing point-of-care workflow and patient-level interventions and opportunities to the exam room. Additionally, our systems of record enable the creation of unique longitudinal records and linked datasets, which brings powerful insights to life sciences organizations. In our second quarter call, I provided an example of what we are doing when I highlighted a recently signed agreement with PRA Health Sciences, which is now part of ICON, to create an EHR-based clinical research network. Another example from our most recent quarter is that we signed a teaming agreement to allow the U.S. Centers for Disease Control and Prevention access to our Health Insights EHR dataset to advance and assist in the CDC's COVID-19 research. The real-world data that we provide will allow CDC scientists to analyze and develop insights related to variants, vaccinations, long-term effects, and other emerging questions related to COVID-19. We increased the strength of our Veradigm platform in the third quarter with approximately 500 new practices and another 2,000 prescribing physicians added to our Veradigm network. The new segment presentation is a good step, and our goal is to continue to increase visibility with respect to Veradigm through our future quarterly calls. Now let me turn to our overall margin performance in the quarter. Consolidated non-GAAP gross margin was 42.4%, which was up 270 basis points year-over-year and continued a steady trend that we have seen all year. Further down the P&L, we continue to manage our operating expenses tightly, and this helped drive very strong 24% year-over-year Adjusted EBITDA growth in the quarter, and it resulted in Adjusted EBITDA margin of 19.3%. On a per share basis, we reported non-GAAP EPS of $0.27 per share, which was up 145% year-over-year, and reflecting our strong margin performance as well as our lower share count. Our accelerated share repurchase program was in effect for most of the quarter, which is why you don't see any incremental cash outlays for share buybacks during the quarter. The ASR is now settled, and we expect to return to opportunistic repurchases in Q4. We had another strong quarter of free cash flow as we generated $57 million of cash flow from continuing operations and $35 million of free cash flow. The strength of our Adjusted EBITDA and free cash flow performance during the quarter has led us to further increase our guidance for the full year as follows. We are increasing our 2021 Adjusted EBITDA outlook to a range of $275 million-$285 million from our prior outlook of $265 million-$275 million. We are also increasing our 2021 free cash flow outlook to a range of $145 million-$155 million from our prior outlook of $115 million-$125 million. With that, I'd like to now open the call for any questions you might have. Thank you. Ladies and gentlemen, if you have a question or comment, it is star one on your telephone keypad at this time. Again, it is star one for any questions or comments. We'll take our first question from George Hill at Deutsche Bank. Your line is open, sir. Please go ahead. Hey, guys. I don't know who that Stuart guy is, but if you find him, he can stand in and update the model for me. I guess, Paul, thanks for taking the question. I kind of have two. Paul and Rick, it seems like everywhere we turn, the one thing that we keep hearing more about is the growth of virtual primary care. I guess, could you talk about how Allscripts is positioned as it relates to that end market? Is it kind of a headwind or tailwind for your clients? Kinda how do you guys think about the opportunity there? I'll come back with another question, second, if that's okay. Yeah. I mean, George, we're glad to hear you didn't have a name change. Thank you. George, I mean, you know, we've adopted a strategy with respect to particularly telehealth and other forms of virtual care, where we're trying to really align with our clients' best interest. We have provided tools to them that allow them to extend their reach from the physical exam room to virtual care. We think that's the right strategy for us to stay aligned with our clients. We have put in very integrated telemedicine tools to our EHRs, to our practice management systems, and we feel pretty good about it. The uptake continues. visits, you know, I don't have any data to give you right now, but I mean, our data continues to grow in terms of the use of those with our clients. Okay, Rick, one for you, if I could follow up. George, sorry. Oops. Sorry, George. I'd also add that, you know, the way that we do too is a bit different in that within the alignment with those clients, not only do we have a single schedule that they can see, so if, you know, somebody else inside the organization at some other point in time can see that there's a, you know, there is a telemedicine scheduled. Secondly, the record itself is actually updated, so you have a single record that's actually updated that has a tele, you know, the result of the tele visit on it as well, not as it's not in a separate silo of information that's disconnected from that patient for that health system. Then thirdly, we also, you know, have a billing component, which is also quite important as you think about the copay as well as you know, the actual billing for that service. We think there's a relatively complete, if you will, system that's required in order to really make this thing be sustainable over a long period of time. Paul, that's helpful. I'll drop two more on you guys real quick, and then I'll hop back in the queue. One's for Rick. It's pretty easy. You guys raised the EBITDA guidance by about $10 million, but the free cash flow guidance by about $30 million. I guess, Rick, could you just talk about where the spread is? My other one for you, Paul, would be, you guys continue to make great progress in Veradigm, and the valuation of assets that look like Veradigm in the market continue to command pretty steep multiples. I guess, could you talk about how you feel about whether there's any value to be unlocked here? I'll hop back in. Thank you, guys. Yeah, I mean, George, I understand the point on the first question. Really the updated guidance ranges are really a reflection of where we are through nine months. We had a very strong quarter in Q3 from a cash flow perspective relative to what I was expecting. With that and where we're at through nine months comes the bigger step up in the range there. That said, I think what we've seen each quarter is pretty indicative of steady state ability for us. I feel good. I don't feel like there's anything unusual in there. I just think you just interpret the new ranges as nine months actual with a kind of a lens towards Q4. On your second question, yeah, I mean, the valuation topic is not lost on us, George. Suffice it to say we're a little frustrated at why we appear to trade at such a large discount to other peers around us. Part of our efforts to create transparency and visibility is to make sure the market understands that. You know, with that, we'll continue to evaluate our options and, you know, make the smartest strategic decisions we think we can. Thanks, guys. Thanks, George. We'll go next to Mike Cherny at Bank of America. Hi, this is Charlotte on for Mike. Thanks for taking my question. It seems like you've, you know, you've seen a lot of margin improvement and you've kind of hit an inflection point in your margins. I guess, how do you think about what you would do with the improved profitability? You know, how do you think about expanding this as we're going into the end of the year? When you say, what would we do with the improved profitability, do you mean in terms of deployment of capital or cash? Sure, yeah. Well, I think, you know, it's. Let's start by looking backwards a little. I mean, we've been pretty aggressive, I would say, with using our balance sheet and our cash to buy back shares. We are very comfortable now where our debt levels are. We're actually below our stated kind of long-term goal of 1.5 turns. We're significantly below that goal. We continue to invest in the business nicely, and so, you know, we've been very aggressive about buying back stock. As I said in my prepared remarks, you know, we will continue to opportunistically come back to the market in Q4. We continue to also evaluate, you know, whether there are things out there that might make sense to add to our asset base as well. We haven't ruled any use of cash out, but we definitely think our stock's cheap, and we think it's a good return for our shareholders to take some of that out. Great. Just a second question here. I think last quarter, you mentioned managing to, you know, higher quality clients, with higher margins versus, quantity of revenue. I guess, can you just describe any benefit that this has had in the quarter and how you're thinking about managing this going forward? Well, we're gonna try to manage with that same attitude and same discipline. It, in part, is a reflection of why our revenue hasn't grown as much in the Hospitals and Large Physician Practice segment. We are trying to emphasize margins and, you know, we have a little pressure at the gross margin level, as you saw in the quarter in that segment, down just slightly from Q2. You know, we're making it up on the operating cost side, too, and it's a combination of our direct cost of sales and our operating costs that we use to service our clients. We are emphasizing margin performance and, you know, we have passed on some opportunities and restructured other opportunities with some of our clients because of those goals. That'll continue to be the way we manage the business going forward. Great. Thank you. Once again, it was star one if you had a question or comment. We'll go next to Sean Dodge at RBC Capital Markets. Yep. Thanks. Good afternoon. Rick, maybe going back to the new cash flow target, the $145 million-$155 million. Can we think about that as a good jumping off point for 2022? Or I know you had some recoveries in Practice Fusion related to the DOJ case. Are those included in there? Is there anything else included in there that we need to think about adjusting out as we you know I guess kind of make our bridges into next year? Yeah, Sean, we had $5 million of recovery, so not a big number, but yes, that does flow through free cash flow, cash flow from operations. So there's maybe a $5 million anomaly. I'd also say we've done a very good job over the last 12 months of managing working capital on the balance sheet. We may have a small, you know, kind of one-time good guy from that. But that's not big money either. I think, you know, those two things aside, what you're seeing from us is what we are capable of doing and what we're committed to continuing to drive. I think it is a good jumping off point. We've had some cash flow in from some of our investment portfolio as well, but that's obviously not in the free cash flow number. In terms of cash to the balance sheet, we have picked up some cash from other places. If you're just trying to model free cash flow or think about that for next year, I would say where we're at, you know, and those two adjustments, then you're got a pretty good starting point. Okay. That's helpful. Thanks. Then on, I guess, on the margins, margin outlook, you've made a lot of progress resetting the cost base. If we take a step back and think about kind of cadence and drivers going forward. Is most of it now gonna be dependent on revenue growth and operating leverage? Or do you think there's still some meaningful opportunities maybe still across the client services organization to pull incremental costs out? You know, there's absolutely continued opportunity, particularly and as you pointed out, in services. I think while we've made tremendous progress over the last six quarters, there is still room to go to drive better profitability in the services areas. That said, you know, we do face, of course, wage pressure, you know. Not lost on anybody that the labor markets are pretty tight right now. We'll have some things that work against us that we have to drive operating efficiencies just to offset. I think, you know, we've grabbed most of the proverbial low-hanging fruit and, but we still have several initiatives around, continuing to get efficiencies out of the workforce and efficiencies out of some areas of our operations like services that will, you know, we expect to, you know, offset some of those other pressures that are coming at us. Okay. Great. Thanks again. We'll go next to Charles Rhyee with Cowen. Your line is open, sir. Please go ahead. Yeah. Thanks, guys. Appreciate taking questions. You know, Paul and Rick, I appreciate the earlier comments about, you know, why we wanna focus on quality clients and we might have passed up some opportunities, you know. But when we look at even on the re-segmented business, you know, I think year-to-date, it's down, you know, roughly 2.5%. Obviously last year was COVID-19, but, you know, back even in 2019, you know, Core Clinical and Financial Solutions I think was down about 1% or so. You know, where do you think we hit sort of an inflection here? Obviously, you've kind of restructured and refocused and done a great job on the margins. You know, is there a point where you expect this area to, you know, cycle back to growth? Then secondly, on Veradigm, you know, looking at these at the supplemental here and about 10% growth in the third quarter, looks like accelerating from about 6.5% last quarter, growth year-over-year. What do you see the growth profile for Veradigm here as, you know, not giving guidance per se, but if we think, you know, over the next, you know, few years, what should the growth profile of this business or do you expect it to be? Well, Charles, let me take your question, and I'll answer in reverse order. You know, Veradigm, you know, we foreshadowed that double-digit growth last call. In some respects, I think we just delivered on what we said. We have a tougher comp in Q4 because we had a really good pop in Q4 of last year with some benefits. You know, I expect fourth quarter to be strong, continue our sequential growth that we're seeing in that business. As I look ahead to 2022, we still look at, you know, double-digit growth being the goal for us. On the first segment, yeah, I mean, it's, I mean, the answer to that is yes. We have seen some shrinking of the business. Some of that is intentional on our part. As I said, we've become a little more discriminating in business. Some of it is still the tail end of some attrition that we talked about a lot last year, I think a little bit earlier this year. We're still kinda winding down a bolus of attrition that we had from some of our larger academic medical centers or larger IDN clients that decided to go in a different direction. We're just about done digesting that. It's a little bit more of a tail to go, but we're just about done digesting that. There is definitely growth opportunities ahead. Paul talked about some of the client successes earlier in his comments. You know, fundamentally, there's kind of three places where we see opportunities. We have opportunity to continue to, you know, gain more wallet share with the client base that we still have, and some of Paul's comments spoke to some success there. We have the ability to compete in the replacement market that exists here in the U.S., and we think our solution set and where we're taking that solution set should be quite competitive there. Then finally, there's outside the U.S., which is a much more of an open white space than we have here in the U.S. We think we're positioned well with some of our points of presence. We think it's a more level playing field outside the U.S., and we have a nice pipeline of opportunities. They're difficult to predict success because they're mostly public sector clients, and the deal times are inherently tough to predict, but they're real. All in, you know, we still like our longer-term prospects in that segment, Charles, but you know, we've gone through a little bit of short-term recalibration, you know, on our way to that. I appreciate that. Maybe just to follow up there. You know, if we were maybe it's a little cherry-picking, but if we were to back out that bolus, that tail of the attrition that you know you're kinda winding down, you know, would you say the underlying, the rest of the business has been growing? Well, we definitely have, you know, success stories that we've shared, and, you know, again, Paul made some comments about some success stories just even from the recent quarter. There are, you know, pieces that are always growing. There are pieces that haven't been growing. The net of that for a few quarters now has been a net decline, but as I said, as we get through the tail end of attrition, which, you know, through next year will mostly be done, we think, then, you know, we hope and expect the netting to turn to a positive. I mean, it's a long way out from now, but that's what our expectation is. That's great. I appreciate it. Thank you, guys. You're welcome. We'll go next to Don Hooker at SVB Leerink. Your line is open. Please go ahead. This is Don Hooker, I guess. I'm at a different firm, but this is Don Hooker at KeyBanc. Am I on- Hi, Don. ...or someone else on? Oh, hey. Okay, it's me. Okay, just making sure it wasn't somebody else. I do not work at Leerink, but that's fine. Wonderful firm. Hey, so I have a couple mundane questions, if you don't mind. Just, I guess, first, what is, you know, you guys are doing a great job kind of buying back stock and generating cash flow. What is the ending share count? I was just fumbling through your numbers here. I'm just sort of thinking about going into Q4 and kinda where you're at in terms of share count. I know it's moving down through the quarter. Where do we start Q4 with? Well, I mean, you see the weighted average on the P&L, right, Don? Yeah, I do. I'm assuming you have the P&L in front of you. Yeah. You know, there really was only a modest change in Q3. Most of, you know, we were in an ASR program for most of the quarter, and so most of the shares under the program were delivered to us when we launched the program at the end of Q2. There was only a small little settlement that happened in Q3. Long-winded way of saying, you know, the average for Q3 should be a pretty decent proxy right now for Q4. Obviously, then what could change that is any incremental buybacks that we do, you know, during this quarter. Okay, super. Hopefully, that helped you. No, super. Thank you. Another kinda quick one for me, I guess. It looks like you guys divested, to be precise, and I was just wondering if that had any. I think that was after the quarter, I believe, and... Sorry, let me finish. Go ahead and finish your question. I'm sorry. Yeah, I think it was after the quarter. I guess my question was, can we expect cash proceeds from that in Q4? It was during the quarter, Don, and there's actually a small gain that's attributed to it that's actually down in our non-operating results. It wasn't a cash deal. We actually rolled the business into another company, and we took a non-controlling stake in that combined entity. We did not pull any cash out, no. Okay. Thank you. That's all I had. Thank you. Great. Thank you. One final reminder, ladies and gentlemen, it's star one if you have a question or comments. We will go next to Stephanie Davis at SVB. Hi, this is Joy Zhang for Stephanie. Just one question from me. We've started to see some of your peers pivot to a surround sound strategy with greater focus on adjacencies across the EHR. Now, you've already made some investments there historically, so I was hoping to hear a refresh on some of the areas in your portfolio where you've got the highest level of excitement and any other adjacencies that you would like to enter. Well, let me talk about the Veradigm segment, and then maybe Paul will make some comments on the Hospitals and Large Physician Practices segment. You know, our adjacencies that we're going after, you know, frankly go well beyond the provider market. You know, that's a lot of what the ambition have been of Veradigm. We've been at it for several years now, and, you know, we've now built what we think is a very unique platform that, not only allows us to have a strong presence with providers and a strong financial return from providers, we're also able to bring that to both the payer and life science end markets as well. I mean, I think that's the ultimate adjacencies that we're pursuing. Inside the provider subset of that, you know, there are definitely strategies to continue to give them what they really need. Some of our smaller practices are very interested in practice management type of solutions and helping them with their revenue cycle, helping them obviously with now telemedicine and other virtual care capabilities. There's a whole host of adjacent products or services, if you will, that we're bringing to the providers. The core strategy is to step out of just the provider world and bring into these other end markets as well. That's what Veradigm's doing. I think on the Hospitals and Large Physician Practices side, you know, Paul, anything you wanna add to that? Yeah, I would say that there's you know a number of concentric circles of opportunity that surround a core EMR install, which is you know fundamentally what we've been doing for over the last nine years in order to maintain and create additional relevance for the company and quite frankly stickiness for the core EMR. What we're doing around the consumer and the digital front door, there's not a single client that's not asking for that kind of capability, and we have that. We have a lot of managed services opportunities as clients are getting pressure on wage. As I said earlier, they're seeing wage inflation. They're seeing some costs go up that they're really trying to control for. There're pieces of the business they're interested in outsourcing to us, and we'll do that in a profitable way. I mentioned, and Rick mentioned also on both sides, the revenue cycle management services. A lot of people through COVID-19, as they sent a lot of folks home, they actually said, since those people are home, they actually could be at home and working for somebody else. RCMS revenue cycle is a very highly automated and becoming very highly predictable experience for clients. Then it sets itself up quite well for SLAs, which are very important to clients, and we're happy to do that as well. The concept around hosting and having on-prem, if you will, kind of capabilities in computers with cyber, with everything else that's gone on. Again, also the deployment of capital on their side. Our hosting business continues to show a lot of promise, especially as we are moving clients to Microsoft Azure, that we had a couple more of them moved over last quarter, and we have, you know, that's a very nice piece of business for us. We do a lot of project work. We have a lot of updates and upgrades that are coming on as a result of the regulatory work in 2022. Our professional services business is not only doing well, but it's also extraordinarily, you know, well run today, and throwing off some nice margins that have historically not been as predictable as what we've had over the last 12 months. The white space, I would say, Rick mentioned it earlier, but when we think about wallet share, there's a lot of clients that are saying they are really looking internally for cost savings, and they're saying, "If I had 700 different relationships, how can I get down to 500?" We've got three or four clients that are doing that right now. In doing that, they're looking to us today for a broader set of solutions that historically weren't here five and six years ago. We are repositioning Allscripts as being a single shop to be able to acquire lots of other software from that historically they've sourced through a different and many times a competitive product. That's super helpful. Thank you. Thank you. You're welcome. With no other questions holding, I will turn the conference back to management for any additional or closing comments. Thank you very much for your time today. We appreciate it, and we're quite pleased with our Q3 results and look forward to talking to you again in another three months. Thank you very much. Ladies and gentlemen, that will conclude today's conference. We thank you for your participation. You may disconnect at this time, and have a great day.